IntroductionDiscontinuation of tyrosine kinase inhibitor (TKI) treatment is emerging as the main therapy goal for Chronic Myeloid Leukemia (CML) patients. The DESTINY trial showed that TKI dose reduction prior to cessation can lead to an increased number of patients achieving sustained treatment free remission (TFR). However. there has been no systematic investigation to evaluate how ... https://parisnaturalfoodes.shop/product-category/vit-a-wrinkle-creme/